Antiviral drugs belong to the class of medicines, which used for treating viral infections, such as HIV, herpes, hepatitis, and influenza. These drugs are generally administered in the form of vaccines.
Portland, OR -- (SBWIRE) -- 10/04/2017 -- The global antiviral drugs market is driven by increase in the incidence rate of viral infections. In addition, rise in R&D activities and development of newer & advanced formulations, such as vaccines and combination therapy, are expected to propel the market growth. However, high cost involved in drug development and growth in the demand for alternative medicines such as naturopathy and homeopathy restrain the market growth. Moreover, development of broad-spectrum antibiotics and growth opportunities in the emerging economies of Asia-Pacific and LAMEA regions are expected to provide numerous opportunities for the market growth during the forecast period.
Early buyers will receive 20% customization on this report
Get PDF Brochure of this report: https://www.alliedmarketresearch.com/request-toc-and-sample/2796
The global antiviral drugs market is segmented on the basis of mechanism of action, type, application, and region. On the basis of mechanism of action, it is divided into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. On the basis of type, it is classified into generic drugs and branded drugs. Based on application, it is categorized into HIV, hepatitis, herpes, influenza, and other viral diseases. The market is analyzed on the basis of region across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
The major companies profiled in the report include F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott Laboratories, AstraZeneca plc., AbbVie Inc., Schering-Plough Corporation, Johnson & Johnson, and Merck & Co., Inc.
Antiviral Drugs Market Key Segments:
By Mechanism of Action
- Nucleotide Polymerase Inhibitors
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- By Application